Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (UG3/UH3)

The summary for the Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (UG3/UH3) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (UG3/UH3): This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support UG3/UH3 phased award Projects as part of the expanded Immuno-Oncology Translational Network (IOTN). The IOTN will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor initiation and progression and evaluating new or improved immunopreventive and immunotherapeutic strategies (including combinations with standard or other therapies). Studies should be largely pre-clinical involving clinically-relevant models and endpoints, and have the potential for rapid translation into early-phase clinical applications. Applicants responding to this FOA must apply for both the UG3 and UH3 phases together in a single application. Exploratory studies aimed at immune target identification and validation will be supported under UG3. Achievement of the UH2 milestones will be necessary for transition to the UH3 Implementation Phase. UH3 phase may be awarded after administrative review of the UH2 milestones. Provided these milestones are achieved, UH3 phase may continue with development and preclinical testing of specific interventions.

Federal Grant Title:	Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (UG3/UH3)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Environment Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-19-012
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.113, 93.121, 93.353, 93.393, 93.853
CFDA Descriptions:	Information not provided
Current Application Deadline:	February 11th, 2019
Original Application Deadline:	February 11th, 2019
Posted Date:	October 31st, 2018
Creation Date:	October 31st, 2018
Archive Date:	March 19th, 2019
Total Program Funding:	$2,000,000
Maximum Federal Grant Award:	$500,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	October 31st, 2018

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-012.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clini...; • Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic ...; • Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clini...; • Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed); • Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clin...; • Outstanding New Environmental Scientist Award (ONES); • Environmental Health Sciences Core Center Grants; • Leiomyomata Uteri: Basic Science and Translational Research
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...